Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Filings indexed 1,226 across all filing types
Latest filing 2021-04-02 Proxy Solicitation & In…
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2021-04-02 English
FORM 4
Director's Dealing
2021-03-30 English
FORM 4
Director's Dealing
2021-03-30 English
FORM 4
Director's Dealing
2021-03-24 English
FORM 3
Director's Dealing
2021-03-16 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 9, 2021, for Innoviva, Inc. The content focuses on the appointment of a new independent director, Deborah L. Birx, to the company's Board of Directors, including her background and committee assignments. There is no financial data or report attached, and the document is not an earnings release, annual report, or other financial filing. The primary subject is a change in the company's board composition, which fits the category of Board/Management Information (MANG). The document length is about 5313 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is MANG with high confidence.
2021-03-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.